MUNDIPHARMA
16.4.2024 11:01:35 CEST | Business Wire | Press release
Mundipharma and Vectura will now progress development of the reformulation of flutiform® (fluticasone propionate/formoterol fumarate) following long-term collaboration, planning and lab-scale development work. The reformulation will ultimately ensure a comparable effective product for patients and further reduce its impact on the environment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240416962162/en/
The product is an established pressurised metered-dose inhaler (pMDI) for the treatment of asthma, where the use of a combination product is appropriate, and has been available on the market for more than a decade.3
It currently uses the approved apaflurane hydrofluoroalkane 227 (HFA-227), a type of fluorinated greenhouse gas, as its propellant.3 European Union regulation on these types of gases aims to reduce their use, and therefore their emissions, by two-thirds by 2030.1
Work is already under way to source an alternative to the HFA-227 gas used in fluticasone propionate/formoterol fumarate pMDI. This new collaboration will revitalise the efforts to identify and switch to a more environmentally friendly propellant. If successful, this will result in a significantly lower impact on global warming and alignment with European Union regulation on fluorinated greenhouse gases.1
With more than 262 million people living with asthma globally, the reformulation of some asthma treatments to reduce carbon emissions could have a significant impact on the global carbon footprint.4,5
“We are dedicated to positively influencing the life of asthma patients across the globe. This is the first step in our long-term plan to develop a near-zero-emissions asthma inhaler. We are determined to achieve this before the European Union ban of HFA (hydrofluoroalkane) gases comes into effect, and our collaboration with Vectura demonstrates this, as well as our aim to an overall commitment to sustainable healthcare innovation,” said Yuri Martina, Chief Development and Medical Officer at Mundipharma.
“At Vectura, our priority is to ensure that patients prescribed fluticasone propionate/formoterol fumarate pMDI can continue to have access to this treatment. Using Vectura’s expertise and extensive track record in the development of inhaled prescription medicines and devices, we believe the collaboration with Mundipharma will enable us to meet our environmental responsibilities and enable patients to use fluticasone propionate/formoterol fumarate pMDI in the years to come,” said Geraldine Venthoye, Chief Scientific Officer, Vectura.
®: FLUTIFORM is a registered trademark of Jagotec AG used under licence by Mundipharma.
References
- Regulation (EU) No 517/2014 of the European Parliament and of the Council of 16 April 2014 on fluorinated greenhouse gases and repealing Regulation (EC) No 842/2006 Text with EEA relevance. Available at: https://eur-lex.europa.eu/legal-content/EN/ALL/?uri=uriserv:OJ.L_.2014.150.01.0195.01.ENG (last accessed March 2024)
- flutiform® pMDI emissions manufacturing data, Q4 2022 – Q4 2023. Data on file.
- flutiform® Summary of Product Characteristics (SmPC). Last updated 13 April 2022. https://www.emcpi.com/pi/26954. (last accessed April 2024).
- Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-22
- NHS England, World Asthma Day: tackling climate change and improving respiratory care. Available at https://www.england.nhs.uk/blog/world-asthma-day-tackling-climate-change-and-improving-respiratory-care/ (last accessed March 2024)
*ENDS*
Job code: SciA-FLU-2400001| Date of preparation: April 2024
|
Notes to Editors
About flutiform® (fluticasone propionate/formoterol fumarate):
flutiform® is an inhaler (a pressurised metered-dose inhalation, suspension) which contains two active ingredients, fluticasone propionate and formoterol fumarate dihydrate.3 This fixed-dose combination of fluticasone propionate and formoterol fumarate (flutiform®) is indicated in the regular treatment of asthma where the use of a combination product (an inhaled corticosteroid and a long-acting β₂ agonist) is appropriate for the management of asthma symptoms.3
About Mundipharma:
Mundipharma is a global healthcare company with a presence across Africa, Asia Pacific, Canada, Europe, Latin America and the Middle East.
Mundipharma is dedicated to bringing innovative treatments to patients in the areas of respiratory, pain management, infectious disease as well as other severe and debilitating disease areas. Our guiding principles, centred around Integrity and Patient-Centricity, are at the heart of everything we do. For more information visit www.mundipharma.com.
About Vectura:
Vectura is a specialist inhalation contract development and manufacturing organization (CDMO) that provides inhaled drug development solutions to help customers bring their medicines to patients. With 25 years’ experience, it provides a combination of formulation science, device technology, and inhaled development expertise. Vectura is a member of the Vectura Fertin Pharma group of companies. For more information visit www.vectura.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240416962162/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lenovo Announces Tech World @ CES 2027: Defining the Next Era of Hybrid AI7.10.2026 15:01:00 CEST | Press release
Lenovo Chairman and CEO Yuanqing Yang to unveil how Hybrid AI turns data into value for every individual and enterprise during CES Keynote at Sphere Lenovo, the global technology powerhouse, today announced that its annual global innovation event will return to CES® 2027 in Las Vegas. Hosted at Sphere and part of the CES Keynote lineup, Tech World will bring together a visionary lineup of speakers and breakthrough innovations with a first-of-its-kind immersive technology and music experience. As well as unveiling the latest in Lenovo’s innovations, Tech World will unite global technology leaders and leading voices on stage to discuss the future of AI. Together, they will explore how hybrid AI can empower people and unlock new possibilities for business and society. As demand grows for responsible AI leadership, the event will provide a defining moment at the start of 2027 to consider AI’s role in unlocking human potential, sustaining the planet, and driving global progress. “AI is ente
NTT DATA Opens AI Factory Munich Where Clients Can Validate their AI in a Live Environment7.10.2026 15:00:00 CEST | Press release
Helping clients move AI from pilots to production in a live, production-grade environmentEnabling organizations to test AI they own and control against their own use cases before making investment decisionsBringing together NTT DATA’s consulting, data, AI, infrastructure, security, operations and managed services expertise with leading technology partners including Dell Technologies and NVIDIA NTT DATA, a global leader in AI, digital business and technology services, today opened the NTT DATA AI Factory Munich, a real-world environment where clients can test how their AI applications will perform at scale before they invest in broad deployments. Unlike a traditional AI demonstration or innovation lab, the AI Factory Munich operates within a live data center environment (NTT Global Data Centers' Munich 2 Data Center), allowing clients to evaluate AI workloads against the infrastructure, security, data, governance and operational requirements they will face in production. AI deployments
Rivercell Launches With $25 Million to Build Data Platforms and AI Models That Predict How Human Cells Respond to Treatment7.10.2026 15:00:00 CEST | Press release
Founded by serial entrepreneur and CEO, Yann Fleureau, and former AI research leader at Novartis and Owkin Eric Durand, Rivercell aims to generate high-resolution data on how human cells respond to treatments at scale and train AI models to predict their effects, ultimately accelerating the discovery and development of cures. Seed round led by HV, with participation from HCVC, Alven, and Bpifrance Digital Venture, to scale Rivercell's proprietary data engine and automated wet lab, and ship the first AI world model of the cell trained on a new data substrate. Eric Durand joins as co-founder and Chief Science Officer (CSO). At Novartis, he successfully supported around 300 drug programs before building Owkin’s data science team as Chief Data Science Officer, giving him first-hand insight into the data that today's bio world models are missing. Leading researchers in AI for biomedicine, Dr. Charlotte Bunne (EPFL) and Prof. Fabian Theis (Helmholtz Munich), join the Scientific Advisory Boar
Print Infrastructure Is the Biggest Zero Trust Gap CIOs Haven’t Closed, Survey Finds7.10.2026 14:30:00 CEST | Press release
54% of CIOs and IT leaders call the risk in their document and print workflows “known and accepted,” even as only 16% have brought print into their Zero Trust architecture Vasion today released new research revealing a security gap hiding in plain sight across enterprise IT: CIOs and IT leaders know their print environments carry risk, but print remains largely outside their Zero Trust strategies even as failures continue to disrupt business operations. According to an independent survey of 500+ enterprise CIOs and senior IT leaders commissioned by Vasion through Censuswide, 54% of respondents describe their print environment as “actively managed, with known and accepted risks.” At the same time, 61% report that print or document workflow failures disrupt their business at least once a week. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261007677295/en/ Print Infrastructure Is the Biggest Zero Trust Gap CIOs Haven’t Closed,
Oscilloquartz expands OSAinside™ Series OSA 5400 TimeCard™ with advanced server-integrated timing capabilities7.10.2026 14:00:00 CEST | Press release
News summary: Enhanced OSA 5400 TimeCard™ brings high-performance synchronization directly into COTS and purpose-built servers Advanced capabilities include PCIe Precision Time Measurement, multi-band GNSS with NavIC and Galileo OSNMA, optional Iridium® PNT and flexible oscillator options OSA 5400 TimeCard™ and OSA 5400 TAP TimeCard™ options support flexible server-integrated timing architectures for defense, data center, telecom and finance applications Oscilloquartz today announced significant new capabilities for its OSAinside™ Series OSA 5400 TimeCard™, expanding the flexibility and performance of server-integrated timing for defense, data center, telecom and finance applications. With support for multiple deployment architectures and timing sources, the enhanced OSA 5400 TimeCard™ enables organizations to integrate highly accurate synchronization directly into commercial off-the-shelf (COTS) and purpose-built servers, reducing reliance on dedicated external timing appliances. Avai
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom